文献速递主动脉疾病

EVAS联合平行支架治疗复杂腹主动脉瘤的早期经验:ASCEND注册研究

Early Experience With Endovascular Aneurysm Sealing in Combination With Parallel Grafts for the Treatment of Complex Abdominal Aneurysms: The ASCEND Registry.
PubMed 文献 · J Endovasc Ther · 2017-09-12

ASCEND注册研究回顾性分析8个血管中心154例肾旁/肾旁腹主动脉瘤患者,采用EVAS联合烟囱支架(chEVAS)择期治疗。30天死亡率为2.8%,1年全因死亡率自由度为89.8%,动脉瘤相关死亡率自由度为94.3%,I型内漏自由度为95.7%。该研究为聚合物技术与平行支架治疗复杂主动脉疾病提供了概念验证。

要点

  • chEVAS治疗复杂腹主动脉瘤30天死亡率为2.8%,围手术期卒中4例(1例致死)。
  • 1年全因死亡率自由度为89.8%,动脉瘤相关死亡率自由度为94.3%。
  • 1年I型内漏自由度为95.7%,再干预自由度为89.2%,靶血管通畅率高。

核心结论

  • ASCEND注册研究支持聚合物技术和EVAS联合平行支架治疗复杂主动脉疾病的概念验证。
  • chEVAS的未来作用需通过评估中远期耐久性的研究来确定。

研究设计与样本

  • 回顾性、多中心注册研究,2013至2016年间在8个血管中心建立。
  • 纳入154例(平均年龄72.3±7.7岁,124例男性)择期治疗的非破裂肾旁和肾旁腹主动脉瘤患者。
  • 记录chEVAS手术的治疗结果和随访数据,采用标准化结局指标分析。

主要发现

  • 30天死亡率为2.8%,围手术期卒中4例(1例致死)。
  • 1年全因死亡率自由度为89.8%,动脉瘤相关死亡率自由度为94.3%。
  • 术后90天内发生3例内漏(1例Ia型,2例Ib型);1年Ia型内漏自由度为95.7%,全因内漏自由度为94.2%。
  • 1年再干预自由度为89.2%;左肾动脉、右肾动脉、肠系膜上动脉和腹腔干支架1年通畅率分别为97.7%、99.3%、100%和100%。

关键数值与推荐

  • 30天死亡率2.8%;1年全因死亡率自由度89.8%,动脉瘤相关死亡率自由度94.3%。
  • 1年Ia型内漏自由度95.7%,全因内漏自由度94.2%;无II型或III型内漏。
  • 1年再干预自由度89.2%。
  • 1年靶血管通畅率:左肾动脉97.7%,右肾动脉99.3%,肠系膜上动脉100%,腹腔干100%。

临床怎么用

  • 对于肾旁和肾旁腹主动脉瘤,chEVAS可作为择期腔内治疗的选项之一。
  • 需关注围手术期卒中和内漏风险,并计划定期随访监测靶血管通畅性和再干预需求。

局限性

  • 回顾性注册研究设计。
  • 随访时间仅1年,缺乏中远期耐久性数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the results of the ASCEND Registry of cases involving endovascular aneurysm sealing (EVAS) in combination with chimney grafts (chEVAS) for the treatment of para- and juxtarenal aortic aneurysms (AAA). METHODS: A retrospective, multicenter registry established in 8 vascular centers between 2013 and 2016 recorded the treatment results and follow-up of chEVAS procedures for nonruptured AAAs; data were analyzed using standardized outcome measures. In the observation period, 154 patients (mean age 72.3±7.7 years; 124 men) underwent elective treatment for de novo juxtarenal and pararenal aneurysms and formed the study group. RESULTS: Sixty-two (40.3%) of the cohort were treated using a single parallel graft, 54 (35.1%) with double chimneys, 27 (17.5%) with triple chimneys, and 11 (7.1%) with 4 chimneys. The 30-day mortality was 2.8%, and there were 4 perioperative strokes (1 fatal). At 1 year, the freedom from all-cause mortality was 89.8% and the freedom from aneurysm-related mortality was 94.3%. There were 3 endoleaks within 90 days of the procedure, one type Ia and 2 type Ib. The freedom from type Ia endoleaks was 95.7% at 1 year. There were no types II or III endoleaks in this series; the freedom from all endoleaks was 94.2% at 1 year. Freedom from reintervention at 1 year was 89.2%. Target vessel patency rates at 1 year were 97.7%, 99.3%, 100%, and 100% for the left renal, right renal, superior mesenteric artery, and celiac axis stents, respectively. CONCLUSION: The ASCEND Registry supports a proof of concept for the use of polymer technology and EVAS with parallel grafts in managing patients with complex aortic disease. The future role of chEVAS will be defined by studies that assess mid- to long-term durability.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Thompson M, Youssef M, Jacob R, et al. Early Experience With Endovascular Aneurysm Sealing in Combination With Parallel Grafts for the Treatment of Complex Abdominal Aneurysms: The ASCEND Registry. J Endovasc Ther. 2017. PMID: 28895447. doi:10.1177/1526602817731103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。